此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Deep Brain Stimulation + Therapy for Stroke

2026年9月23日 更新者:Jorge Gonzalez-Martinez、Pirondini, Elvira, PhD

Deep Brain Stimulation of the Motor Thalamus Combined With Speech and Swallowing Therapy to Improve Post-Stroke Motor Speech and Swallowing Production Impairments

The purpose of this study is to evaluate the safety and potential benefits of combining deep brain stimulation (DBS) with targeted speech and swallowing rehabilitation in individuals who have experienced a stroke and have moderate to severe difficulties with speech and/or swallowing. Speech difficulties may include apraxia, which affects the ability to plan and coordinate speech movements, and dysarthria, which affects the ability to produce clear speech. Participants may also have difficulty swallowing (dysphagia).

The primary objective of this feasibility study is to evaluate the safety of the SR-DBS system in individuals with post-stroke speech and swallowing difficulties. The secondary objective is to evaluate whether combining DBS with speech and swallowing rehabilitation improves motor speech and swallowing function and reduces related impairments. The study will compare outcomes following rehabilitation alone with outcomes following rehabilitation combined with DBS to determine whether the addition of DBS provides greater improvements in speech and swallowing function.

研究概览

详细说明

The study will be conducted in three sequential phases. Following baseline assessments, participants will complete a structured speech and swallowing therapy program in Phase 1 (Rehabilitation), consisting of 60-minute sessions 3 days per week for 6 weeks, with 45 minutes dedicated to speech therapy and 15 minutes to swallowing therapy. In Phase 2 (Rehabilitation + DBS), participants will undergo implantation of the Stroke Rehabilitation Deep Brain Stimulation (SR-DBS) System and complete the same 6-week therapy program, with DBS delivered during the therapy sessions. Each session will include 45 minutes of speech therapy and 15 minutes of swallowing therapy. In Phase 3, implanted participants will be followed for 6 months after the intervention, with monthly laboratory visits to assess the effects of DBS on speech and swallowing function.

研究类型

介入性

注册 (估计的)

15

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Cierra Clark, MS
  • 电话号码:2404414216
  • 邮箱:cic27@pitt.edu

研究联系人备份

学习地点

    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • University of Pittsburgh
        • 首席研究员:
          • Jorge Gonzalez-Martinez, MD, PhD
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

22年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Participants must have suffered an ischemic or hemorrhagic stroke causing motor speech and swallowing deficits as a result. For ischemic stroke, the event needs to have occurred more than 6 months before the time of enrollment, whereas, for hemorrhagic stroke, the event needs to have occurred more than 12 months before the time of enrollment. Prior strokes that did not cause motor speech or swallowing deficits are not exclusionary.
  2. Participants must be between the ages of 22 and 75 years old.
  3. English speaker.
  4. Participants must have 30-84% intelligibility on the Speech Intelligibility Test (SIT), score ≤14 on the Communicative Participation Item Bank (CPIB) AND an instrumental swallowing assessment (VFSS or FEES) demonstrating Penetration-Aspiration-Scale (PAS) ≥ 2.

Exclusion Criteria:

  1. Participants must not have any serious disease or disorder (e.g., neurological conditions other than stroke, cancer, severe cardiac or respiratory disease, renal failure, etc.) that could affect their ability to participate in this study.
  2. Participants must not have a high risk of recurrent stroke as evident from their medical history or upon judgment of the study physician.
  3. Participants must not have a score on the Short Blessed Test assessment scale of ≥10.
  4. Female participants of child-bearing age must not be pregnant or breastfeeding during the study.
  5. Participants that cannot suspend their antiplatelets and/or anticoagulant therapy including aspirin, clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta), warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa) for two weeks around the surgery will be excluded from participation.
  6. Participants may not have any implanted medical device that is not MRI safe and must not have any active medical devices, including implanted stimulation devices, even if they are MRI safe.
  7. Participants cannot have severe claustrophobia that can prevent them from executing the required MRI imaging sessions.
  8. Participants must not be taking oral or systemic anti-spasticity or anti-epileptic medications or facial and/or neck anti-spasticity injections (e.g., cosmetic Botox, migraine treatment, or bruxism/TMJ treatment) for 3 months prior to enrollment in the study and for the duration of the study. Participants may continue anti-spasticity injections localized to the upper- and/or lower-limbs.
  9. Participants with a T-score >63 on the 18-question Brief Symptoms Inventory (BSI-18) who have undergone discussions with and been deemed unsuitable by the Principal Investigator, and a study physician will be excluded from participation.
  10. Participants with gross anatomical variances in MR imaging or cerebral vascular accidents involving motor thalamus and cerebellar areas.
  11. Participants must not have any lesions in the lower motoneuron causing flaccid dysarthria and/or bulbar dysphagia.
  12. Participants with deficits affecting language (i.e., pure aphasia) and not speech deficits.
  13. Participants with diabetes mellitus whose recent Hemoglobin A1C value is 8.0% or greater.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Rehabilitation Alone, then Combined with Deep Brain Stimulation

Two Vercise™ Cartesia™ X Directional Leads (16-contact) - Model DB-2203 (P150031 - S065) will be surgically implanted bilaterally in the thalamus for the duration of Phases 2 and 3. The leads will be connected to a Vercise Genus R32 IPG (P150031 - S050), which will be surgically implanted in the chest and remain implanted for the duration of Phases 2 and 3. The IPG is rechargeable.

The Vercise Genus R32 IPG (P150031 - S050) is a rechargeable implantable pulse generator designed to deliver electrical stimulation to the thalamus via two surgically implanted Vercise™ Cartesia™ X Directional Leads (16-contact), Model DB-2203 (P150031 - S065). The system will be used for the duration of Phases 2 and 3.

The speech and swallowing training protocol (Rehab) is designed to engage with tailored exercises for speech and swallowing. For speech, the training exercises will be executed following the "Be Clear" program, which has been extensively validated in participants with non-progressive dysarthria and apraxia and has been recently shown to be effective also when administered through telemedicine. For swallowing, the training exercises will be based on the Intensive Dysphagia Rehabilitation protocol, developed for adults with neurogenic dysphagia.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number and Severity of Adverse Events
大体时间:From enrollment to the end of treatment at 49 weeks

Success Criteria: No serious adverse events related to the stimulation or intolerable adverse events reported.

From enrollment to the end of treatment at 49 weeks

次要结果测量

结果测量
措施说明
大体时间
Absolute PAS Change - Phase 2
大体时间:11 weeks

The investigators will measure the change in the Penetration Aspiration Scale (PAS) from post-implant to the end of Phase 2 with stimulation off. The PAS is an 8-point medical rating system used to describe how deep food, liquid, or saliva goes into a person's airway during a swallow. Scores range from 1 to 8, with lower scores indicating better swallowing function and higher scores indicating worse swallowing function. Success criteria: Mean change in PAS score across Phase 2 is greater than zero, indicating an additional therapeutic benefit of DBS beyond speech and swallowing training executed in Phase 1.

11 weeks
Absolute PAS Change - Baseline to Phase 2
大体时间:19 weeks

The investigators will measure the change in the Penetration Aspiration Scale (PAS) from baseline to the end of Phase 2 with stimulation off. The PAS is an 8-point medical rating system used to describe how deep food, liquid, or saliva goes into a person's airway during a swallow. Scores range from 1 to 8, with lower scores indicating better swallowing function and higher scores indicating worse swallowing function. Success criteria: Mean change in PAS score across the study period is greater than zero.

19 weeks
Absolute Intelligibility - Phase 2
大体时间:11 weeks

The investigators will measure the change in intelligibility from the Speech Intelligibility Test (SIT) from post-implant to the end of Phase 2 with stimulation off. The SIT is a clinical tool used to measure how clearly a person speaks and how well an unfamiliar listener can understand them. The SIT score ranges from 0% to 100%, with higher scores indicating better speech intelligibility and lower scores indicating worse speech intelligibility. It is calculated by counting the number of correct words, dividing that by the total number of words in the target stimulus, and multiplying that by 100 to calculate the percent-correct intelligibility score. Success criteria: Mean change in intelligibility across Phase 2 is greater than zero, indicating an additional therapeutic benefit of DBS beyond speech and swallowing training executed in Phase 1.

11 weeks
Absolute Intelligibility - Baseline to Phase 2
大体时间:19 weeks

The investigators will measure the change in intelligibility from the Speech Intelligibility Test (SIT) from baseline to the end of Phase 2 with stimulation off. The SIT is a clinical tool used to measure how clearly a person speaks and how well an unfamiliar listener can understand them. The SIT score ranges from 0% to 100%, with higher scores indicating better speech intelligibility and lower scores indicating worse speech intelligibility. It is calculated by counting the number of correct words, dividing that by the total number of words in the target stimulus, and multiplying that by 100 to calculate the percent-correct intelligibility score. Success criteria: Mean increase in intelligibility across the study period is equal or greater than 15 percentage points, indicating the average improvement surpasses the minimal clinically meaningful threshold.

19 weeks
Modified Barium Swallow Impairment Profile Changes - Phase 2 to Phase 3
大体时间:31 weeks

The investigators will measure changes in the Modified Barium Swallow Impairment Profile (MBSImP) scores with stimulation on and stimulation off during the same session. The MBSImP evaluates 17 distinct physiological components of swallowing, grouped into three main operational domains. Each component is rated on an ordinal impairment scale, with scores ranging from 0 (normal swallowing function) to 3 to 5 points depending on the specific physiological measure. Lower scores indicate less swallowing impairment and better swallowing function, while higher scores indicate greater swallowing impairment. Success criteria: 75% of participants will have significantly lower MBSImP scores with DBS ON compared to DBS OFF. This will confirm that DBS can immediately improve swallowing function.

31 weeks
Motor Speech Function - Frenchay Dysarthria Assessment
大体时间:31 weeks

The investigators will measure changes in Frenchay Dysarthria Assessment-Second Edition (FDA-2) scores with stimulation on and stimulation off during the same session. The FDA-2 uses a 9-point rating scale, ranging from 1 (severe impairment) to 9 (normal function), with higher scores indicating better motor speech function. Participants will complete either of the motor speech function assessments depending on the nature of their motor speech impairments (i.e., dysarthria vs. apraxia) as identified by a speech-language pathologist prior to speech and swallowing training in Phase 1. Participants with both dysarthria and apraxia will complete both assessments. Success criteria: 75% of participants will have significantly improved scores on the FDA-2 (i.e., higher score) with DBS ON compared to DBS OFF. This will confirm that DBS can immediately improve motor speech function.

31 weeks
Motor Speech Function - Apraxia Battery for Adults
大体时间:31 weeks

The investigators will measure changes in Apraxia Battery for Adults-Second Edition (ABA-2) scores with stimulation on and stimulation off during the same session. The ABA-2 assesses multiple aspects of motor speech and praxis, with subtest scores ranging from 0 to the maximum value specified for each subtest; higher or lower scores indicate better performance depending on the subtest. Participants will complete either of the motor speech function assessments depending on the nature of their motor speech impairments (i.e., dysarthria vs. apraxia) as identified by a speech-language pathologist prior to speech and swallowing training in Phase 1. Participants with both dysarthria and apraxia will complete both assessments. Success criteria: 75% of participants will have significantly improved scores on the ABA-2 (i.e., higher or lower score depending on the subsection) with DBS ON compared to DBS OFF. This will confirm that DBS can immediately improve motor speech function.

31 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jorge Gonzalez-Martinez, MD, PhD、University of Pittsburgh

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月1日

初级完成 (估计的)

2030年7月1日

研究完成 (估计的)

2030年7月1日

研究注册日期

首次提交

2026年9月16日

首先提交符合 QC 标准的

2026年9月23日

首次发布 (实际的)

2026年9月30日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All of the individual participant data collected during the trial, after deidentification, may be shared with other researchers for the purpose of data analysis and collaboration.

IPD 共享时间框架

Data will become available at the end of the trial upon publication of the first manuscript. Estimation is 2 years from enrollment of first participant.

IPD 共享访问标准

Data must be directly requested to the PI and will be shared upon completion of necessary data sharing agreement to protect confidential patient information.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅